Lv1
90 积分 2024-04-11 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
1小时前
待确认
Phase I/II Study of Tifcemalimab, an Anti-B and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
4个月前
已完结
Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
9个月前
已完结
[Retrospectively analysis of characteristics and risk factors of immune treatment-related hepatic adverse events in malignant tumor]
1年前
已完结
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
1年前
已完结
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
1年前
已完结
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
1年前
已完结
Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations
1年前
已完结
c‐Met inhibition enhances chemosensitivity of human ovarian cancer cells
1年前
已完结
皖公网安备34019202002308
